Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP, CHIEF FINANCIAL OFFICER | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,677 |
Reported balance
After 2026-08-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-05 · Exercise / conversion · Acquired 5,849 · Balance 73,677 F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 67,828 |
Reported balance
After 2026-08-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-05 · Sale · Disposed 5,849 · Balance 67,828 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Common StockSEC Table I · non-derivative | Direct | 82,120 |
Reported balance
After 2026-08-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Acquired 14,292 · Balance 82,120 |
| Common StockSEC Table I · non-derivative | Direct | 77,120 |
Reported balance
After 2026-08-06 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-08-06 · Sale · Disposed 5,000 · Balance 77,120 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 67,828 |
Reported balance
After 2026-08-06 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-08-06 · Sale · Disposed 9,292 · Balance 67,828 F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24 | Direct | 74,715 |
Reported balance
After 2026-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-05 · Exercise / conversion · Disposed 5,849 · Balance 74,715 F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24 | Direct | 60,423 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Exercise / conversion · Disposed 14,292 · Balance 60,423 F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,292 | $0.00 Strike: $17.84 | $0.00 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · derivative · entry 7 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,423 Underlying: Common Stock · 14,292 shares Expires 2034-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 9,292 | $29.34 | $272,604.05 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,828 F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,000 | $29.00 | $145,000.00 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,120 F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 14,292 | $17.84 | $254,969.28 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,849 | $0.00 Strike: $17.84 | $0.00 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · derivative · entry 6 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,715 Underlying: Common Stock · 5,849 shares Expires 2034-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,849 | $29.00 | $169,637.96 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,828 F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,849 | $17.84 | $104,346.16 |
DisclosureSEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan. Read SEC document |
| May 04, 2026 Filed May 5, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,506 | $21.79 | $76,395.74 |
DisclosureSEC source: 0001899977-26-000007 · form4-05052026_060501.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,145 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.7932, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2026 Filed May 5, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-26-000007 · form4-05052026_060501.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,815 Underlying: Common Stock · 6,815 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2026 Filed May 5, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,815 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-26-000007 · form4-05052026_060501.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 07, 2026 Filed Apr 7, 2026 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,709 | $22.20 | $60,139.80 |
DisclosureSEC source: 0001899977-26-000005 · form4-04072026_110411.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,836 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| April 05, 2026 Filed Apr 7, 2026 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-26-000005 · form4-04072026_110411.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2026 Filed Apr 7, 2026 23:57 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-26-000005 · form4-04072026_110411.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 37 | $21.72 | $803.54 |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,269 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,171 | $21.65 | $68,652.15 |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,306 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · derivative · entry 7 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,358 Underlying: Common Stock · 6,178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,177 | $21.47 | $89,680.19 |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,299 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · derivative · entry 6 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,414 Underlying: Common Stock · 8,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document |
| March 24, 2026 Filed Mar 27, 2026 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 26,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-26-000002 · form4-03102026_060310.xml · derivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,382 Underlying: Common Stock · 26,382 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 90,691 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001899977-26-000002 · form4-03102026_060310.xml · derivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,691 Underlying: Common Stock · 90,691 shares Expires 2036-03-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 10,262 | $23.69 | $243,113.96 |
DisclosureSEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,338 F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-25-000006 · form4-11192025_061103.xml · derivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-25-000006 · form4-11192025_061103.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 327 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,498 | $23.65 | $82,727.70 |
DisclosureSEC source: 0001899977-25-000004 · form4-09162025_100915.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,447 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 6,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001899977-25-000004 · form4-09162025_100915.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,945 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 22,000 | $25.18 | $554,023.80 |
DisclosureSEC source: 0001415889-25-022359 · form4-08192025_060803.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,130 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 16, 2025 Filed May 20, 2025 00:50 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0001415889-25-013741 · form4-05202025_120539.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,130 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. F2 · balance_after: Includes 1,357 shares of the Issuer's common stock acquired by the Reporting Person on May 15, 2025 pursuant to an employee stock purchase plan. Read SEC document |
| May 02, 2025 Filed May 2, 2025 23:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,498 | $14.60 | $51,070.80 |
DisclosureSEC source: 0001415889-25-011872 · form4-05022025_110505.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,773 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| May 01, 2025 Filed May 2, 2025 23:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011872 · form4-05022025_110505.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,630 Underlying: Common Stock · 6,815 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2025 Filed May 2, 2025 23:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,815 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011872 · form4-05022025_110505.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 23:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,708 | $14.82 | $40,132.56 |
DisclosureSEC source: 0001415889-25-010424 · form4-04082025_110409.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,456 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| April 05, 2025 Filed Apr 8, 2025 23:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010424 · form4-04082025_110409.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,276 Underlying: Common Stock · 5,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2025 Filed Apr 8, 2025 23:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010424 · form4-04082025_110409.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,171 | $17.05 | $54,065.55 |
DisclosureSEC source: 0001415889-25-009074 · form4-03272025_120306.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,889 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,536 Underlying: Common Stock · 6,178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009074 · form4-03272025_120306.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 32,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,552 Underlying: Common Stock · 32,552 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 110,761 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,761 Underlying: Common Stock · 110,761 shares Expires 2035-03-23 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 23:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 773 | $19.96 | $15,429.08 |
DisclosureSEC source: 0001415889-25-005574 · form4-02252025_110254.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,882 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 23:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005574 · form4-02252025_110254.xml · derivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 23:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-005574 · form4-02252025_110254.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 01:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 10,259 | $16.81 | $172,453.79 |
DisclosureSEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 3 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,302 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.768 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 17, 2024 Filed Nov 20, 2024 01:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027292 · form4-11202024_011103.xml · derivative · entry 5 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2024 Filed Nov 20, 2024 01:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027292 · form4-11202024_011103.xml · derivative · entry 4 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| November 17, 2024 Filed Nov 20, 2024 01:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 2 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 17, 2024 Filed Nov 20, 2024 01:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 1 Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.